Literature DB >> 25443885

Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.

Peter Valent1, Karl Sotlar2, Wolfgang R Sperr3, Andreas Reiter4, Michel Arock5, Hans-Peter Horny2.   

Abstract

Mast cell leukemia (MCL) is a rare form of systemic mastocytosis characterized by leukemic expansion of mostly immature mast cells, organ damage, drug-resistance, and a poor prognosis. Even when treated with chemotherapy, most patients have a life-expectancy of less than one year. However, there are rare patients with MCL in whom the condition is less aggressive and does not cause organ damage within a short time. In these patients, mast cells exhibit a more mature morphology when compared to acute MCL. A recently proposed classification suggests that these cases are referred to as chronic MCL. In the present article, we discuss clinical, histopathological and morphological aspects of acute and chronic MCL.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic mast cell leukemia; KIT mutation; Mast cells; Mastocytosis

Mesh:

Year:  2014        PMID: 25443885      PMCID: PMC4896385          DOI: 10.1016/j.leukres.2014.09.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  41 in total

1.  CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

Authors:  Karl Sotlar; Hans-Peter Horny; Ingrid Simonitsch; Manuela Krokowski; Karl J Aichberger; Matthias Mayerhofer; Dieter Printz; Gerhard Fritsch; Peter Valent
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

2.  Mast cell leukemia: report of a case and review of the literature.

Authors:  W D Travis; C Y Li; H C Hoagland; L B Travis; P M Banks
Journal:  Mayo Clin Proc       Date:  1986-12       Impact factor: 7.616

3.  Comprehensive mutational profiling in advanced systemic mastocytosis.

Authors:  Juliana Schwaab; Susanne Schnittger; Karl Sotlar; Christoph Walz; Alice Fabarius; Markus Pfirrmann; Alexander Kohlmann; Vera Grossmann; Manja Meggendorfer; Hans-Peter Horny; Peter Valent; Mohamad Jawhar; Martina Teichmann; Georgia Metzgeroth; Philipp Erben; Thomas Ernst; Andreas Hochhaus; Torsten Haferlach; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Blood       Date:  2013-08-19       Impact factor: 22.113

4.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

5.  Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

Authors:  R Fritsche-Polanz; J H Jordan; A Feix; W R Sperr; G Sunder-Plassmann; P Valent; M Födinger
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

6.  Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Authors:  Sophie Georgin-Lavialle; Ludovic Lhermitte; Felipe Suarez; Ying Yang; Sébastien Letard; Katia Hanssens; Frédéric Feger; Amédée Renand; Chantal Brouze; Danielle Canioni; Vahid Asnafi; Marie-Olivia Chandesris; Achille Aouba; Paul Gineste; Elizabeth Macintyre; Colin D Mansfield; Alain Moussy; Yves Lepelletier; Patrice Dubreuil; Olivier Hermine
Journal:  Eur J Haematol       Date:  2012-04-28       Impact factor: 2.997

Review 7.  Mast cell leukemia.

Authors:  Sophie Georgin-Lavialle; Ludovic Lhermitte; Patrice Dubreuil; Marie-Olivia Chandesris; Olivier Hermine; Gandhi Damaj
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

8.  Molecular defects in mastocytosis: KIT and beyond KIT.

Authors:  Siham Bibi; Florent Langenfeld; Sylvie Jeanningros; Fabienne Brenet; Erinn Soucie; Olivier Hermine; Gandhi Damaj; Patrice Dubreuil; Michel Arock
Journal:  Immunol Allergy Clin North Am       Date:  2014-05       Impact factor: 3.479

9.  A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone.

Authors:  M Baghestanian; H c Bankl; C Sillaber; W J Beil; T Radaszkiewicz; W Füreder; J Preiser; M Vesely; G Schernthaner; K Lechner; P Valent
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

10.  Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.

Authors:  Magalie Joris; Sophie Georgin-Lavialle; Marie-Olivia Chandesris; Ludovic Lhermitte; Jean-François Claisse; Danielle Canioni; Katia Hanssens; Gandhi Damaj; Olivier Hermine; Mohammed Hamidou
Journal:  Case Rep Hematol       Date:  2012-09-10
View more
  10 in total

Review 1.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

2.  Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

Authors:  D J DeAngelo; T I George; A Linder; C Langford; C Perkins; J Ma; P Westervelt; J D Merker; C Berube; S Coutre; M Liedtke; B Medeiros; D Sternberg; C Dutreix; P-A Ruffie; C Corless; T J Graubert; J Gotlib
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

3.  Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis.

Authors:  Dmitri Atiakshin; Igor Buchwalow; Peter Horny; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2021-01-25       Impact factor: 4.304

4.  Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant.

Authors:  Sukesh Manthri; Patrick N Costello; Koyamangalath Krishnan
Journal:  BMJ Case Rep       Date:  2020-08-24

5.  Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).

Authors:  P Savini; M Rondoni; G Poletti; A Lanzi; O Quercia; S Soverini; C De Benedittis; G Musardo; G Martinelli; G F Stefanini
Journal:  Case Rep Hematol       Date:  2015-02-10

6.  Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy.

Authors:  Min Yang; Zengkai Pan; Kezhi Huang; Guntram Büsche; Friedrich Feuerhake; Anuhar Chaturvedi; Danian Nie; Michael Heuser; Felicitas Thol; Nils von Neuhoff; Arnold Ganser; Zhixiong Li
Journal:  Oncotarget       Date:  2017-05-19

Review 7.  Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond.

Authors:  Bettina Sprinzl; Georg Greiner; Goekhan Uyanik; Michel Arock; Torsten Haferlach; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

Review 8.  Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

Authors:  Siba El Hussein; Helen T Chifotides; Joseph D Khoury; Srdan Verstovsek; Beenu Thakral
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

9.  Acute abdomen due to anaphylactic intestinal edema associated with systematic mastocytosis: a case report.

Authors:  Tomoko Takagishi; Katsuhiko Miki; Shinsaku Imashuku; Katsushige Takagishi
Journal:  Int J Emerg Med       Date:  2022-08-24

10.  Acute aleukemic mast cell leukemia: Report of a case and review of the literature.

Authors:  Gian M Galura; Sundar V Cherukuri; Nawar Hakim; Sumit Gaur; Attilio Orazi
Journal:  Leuk Res Rep       Date:  2020-11-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.